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Introduction
□  Osteoporosis is a common disease of the bones that is characterized by 
a decrease in bone density and bone strength, resulting in bone 
fragility.1
□  In the United States, approximately 44 million people have low bone 
density, 10 million of whom have osteoporosis and 34 million with 
osteopenia.2 This equates to about 55% of the U.S. population aged 50 
years and older. The number of people with osteoporosis-related 
fractures is predicted to increase dramatically due to the aging 
population of the country.2
□  Osteoporotic bone fractures are responsible for pain, decreased quality 
of life, lost workdays, and disability.
□  It is important to identify and test patients at high risk for developing 
osteoporosis, as well as implement strategies to help prevent or delay 
the onset of this disease.
□  Pharmacists play a critical role in our healthcare system since they are 
easily accessible in the community.
Objectives
□  To develop and implement models pharmacists can utilize in a 
community pharmacy setting to test and identify patients at risk for 
osteoporosis.
□  To determine the feasibility of implementing this model in additional 
community pharmacy locations.
Methods
□  Patients will be recruited through a computer-generated report 
identifying females aged 50 years or older and females 18 years or 
older and taking medications (Table 1) that lower bone density. These 
patients must have filled a prescription at the community pharmacy 
within the past 6 months.
□  Patients presenting to the pharmacy with identified risk factors will also 
be offered screening.
□  The Simple Calculated Osteoporosis Risk Estimation (SCORE) risk 
assessment tool will be completed on the patients to identify their risk 
for developing osteoporosis. This tool was selected because it has 
been validated in women in multiple studies for predicting low bone 
mineral density (BMD) and osteoporotic fracture.
Methods Cont.
□  Patients exhibiting moderate to high risk for developing osteoporosis 
based on their SCORE result will be offered BMD screening using a 
portable heel ultrasound densitometer (Hologic Sahara Bone 
Densitometer), which will determine T-scores. There will be no additional 
cost to patients for participating in this study.
□  Those patients with 2 risk factors for osteoporosis and a T-score below 
-1.0 or those patients with 0-1 risk factors and a T-score below -2.0 will 
be referred to their physician for dual-energy x-ray absorptiometry and/or 
pharmacotherapy.
□  Every patient that completes the BMD screening will be offered 
personalized consultation on osteoporosis by a pharmacist. At 6 to 8 
weeks after BMD screening, patients will be contacted by telephone for 
follow-up on physician referral, as well as any behaviors initiated and/or 
medications modified.
□  Inclusion Criteria: females 50 years or older and females 18 years of 
age and older and taking medications that lower bone density (Table 1).
□  Exclusion Criteria: Males, patients under the age of 18, females who 
are pregnant, patients whose skin is abraded and/or have an open sore 
in the area that comes in contact with the system, patients who have 
received a dual-energy x-ray absorptiometry in the past 2 years.
□  Data Collection: Patient demographic information survey (including 
education level, yearly household income and amount willing to pay for 
BMD test), SCORE risk assessment results, and T-scores from BMD 
readings. The entire amount of time a pharmacist would need to perform 
the duties from screening to counseling will also be recorded.
□  The study protocol has been approved by the university IRB committee.
Table 1: Medications Associated With Osteoporosis1
Anticoagulants (heparin, warfarin, LMWH: dalteparin, enoxaparin)
Anticonvulsants (carbamazepine, divalproex sodium, gabapentin, 
lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, 
phenytoin, topiramate, valproic acid)
Cyclosporine A and tacrolimus
Cancer chemotherapy drugs (anastrozole, letrozole, leuprolide)
‘ Glucocorticoids (betamethasone, dexamethasone, hydrocortisone, 
methylprednisolone, prednisone, prednisolone, traimacinolone)
Lithium
Methotrexate
Thyroxine
* Glucocorticoids: s 5 mg/d of prednisone or equivalent for a 3 months2
Results
□  Data collection period is expected to last for four months, starting from 
December 2014 to March 2015. To date, no patients have been tested 
for osteoporosis.
□  Initial computer-generated report identified 41 females aged 18 years 
and older on medications that lower bone density.
□  Second computer-generated report identified 528 females aged 50 
years and older.
□  Descriptive statistics will be used to assess data.
Limitations
□  Exclusion of males from the study protocol may not be representative of 
the general population.
□  Travel distance may prevent identified patients from participating in the 
study.
□  Although the counseling information is standardized, differences in 
pharmacists’ consultation techniques may lead to variations in 
information presented to patients.
Implications
□  The results of this project will help to determine the role of pharmacists 
in osteoporosis testing in healthcare settings.
□  Patients’ awareness of osteoporosis, including preventive and treatment 
options, will increase.
□  This project will determine whether this program model can be 
implemented in other community pharmacy locations.
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